Melvin Spigelman

TB Alliance — United States

Medicine · Health Sciences

30h-index6.3kcitations71works32.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(37), Mycobacterium research and diagnosis(11), Pneumonia and Respiratory Infections(9), Infectious Diseases and Tuberculosis(8), Pneumocystis jirovecii pneumonia detection and treatment(7)

Publications71 total

Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps
Antimicrobial Agents and Chemotherapy·2024· 17 citedOpen Access
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
The Lancet Infectious Diseases·2024· 48 citedOpen Access
Standards for clinical trials for treating TB
The International Journal of Tuberculosis and Lung Disease·2023· 4 citedOpen Access
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial
The Lancet Respiratory Medicine·2023· 79 citedOpen Access
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
New England Journal of Medicine·2022· 318 citedOpen Access
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
New England Journal of Medicine·2022· 511 citedOpen Access
Reply to Kaye and Belley, “Third-Generation Cephalosporin-Resistant <i>Enterobacterales</i> Are Critical Priority Pathogens, Too!”
Antimicrobial Agents and Chemotherapy·2022· 2 citedOpen Access
Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed.
Oxford University Research Archive (ORA) (University of Oxford)·2022· 221 citedOpen Access
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
BMJ Open·2021· 29 citedOpen Access
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
The International Journal of Tuberculosis and Lung Disease·2021· 30 citedOpen Access
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
The International Journal of Tuberculosis and Lung Disease·2021· 61 citedOpen Access
Priority Areas for Research on Anti-Tuberculosis Treatment
2021
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
New England Journal of Medicine·2020· 964 citedOpen Access
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
The Lancet Respiratory Medicine·2019· 143 citedOpen Access
Daily Dosing for Bedaquiline in Patients with Tuberculosis
Antimicrobial Agents and Chemotherapy·2019· 30 citedOpen Access
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status
BMC Pulmonary Medicine·2019· 3 citedOpen Access
Analysis of the clinical antibacterial and antituberculosis pipeline
The Lancet Infectious Diseases·2018· 214 cited
Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study
BMC Medicine·2018· 37 citedOpen Access
Toxicity associated with tuberculosis chemotherapy in the REMoxTB study
BMC Infectious Diseases·2018· 37 citedOpen Access
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study
BMC Medicine·2018· 73 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Carl M. Mendel(12), Rosario A. Zappulla(11), James F. Holland(11), Angela M. Crook(9), Timothy D. McHugh(9), Rodney Dawson(9), Leonard I. Malis(9), Ann M. Ginsberg(8), Daniel E. Everitt(8), Francesca Conradie(7), Genevieve H. Wills(7), Stephen H. Gillespie(7), Andrew Nunn(6), Andreas H. Diacon(5), Nosipho Ngubane(5), Robert Hunt(5), Christo van Niekerk(5), Morounfolu Olugbosi(5), Ebrahim Variava(5), Conor Tweed(5)